HRP20161771T1 - Formulacije bendamustina - Google Patents

Formulacije bendamustina

Info

Publication number
HRP20161771T1
HRP20161771T1 HRP20161771TT HRP20161771T HRP20161771T1 HR P20161771 T1 HRP20161771 T1 HR P20161771T1 HR P20161771T T HRP20161771T T HR P20161771TT HR P20161771 T HRP20161771 T HR P20161771T HR P20161771 T1 HRP20161771 T1 HR P20161771T1
Authority
HR
Croatia
Prior art keywords
bendamustine
formulations
Prior art date
Application number
HRP20161771TT
Other languages
English (en)
Inventor
Nagesh R. Palepu
Philip Christopher Buxton
Original Assignee
Eagle Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44309429&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20161771(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eagle Pharmaceuticals, Inc. filed Critical Eagle Pharmaceuticals, Inc.
Publication of HRP20161771T1 publication Critical patent/HRP20161771T1/hr
Publication of HRP20161771T4 publication Critical patent/HRP20161771T4/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
HRP20161771TT 2010-01-28 2016-12-22 Formulacije bendamustina HRP20161771T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29910010P 2010-01-28 2010-01-28
EP11737745.7A EP2528602B2 (en) 2010-01-28 2011-01-28 Formulations of bendamustine
PCT/US2011/022958 WO2011094565A1 (en) 2010-01-28 2011-01-28 Formulations of bendamustine

Publications (2)

Publication Number Publication Date
HRP20161771T1 true HRP20161771T1 (hr) 2017-02-24
HRP20161771T4 HRP20161771T4 (hr) 2020-08-07

Family

ID=44309429

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20161771TT HRP20161771T4 (hr) 2010-01-28 2016-12-22 Formulacije bendamustina
HRP20210915TT HRP20210915T1 (hr) 2010-01-28 2021-06-09 Formulacije bendamustina

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20210915TT HRP20210915T1 (hr) 2010-01-28 2021-06-09 Formulacije bendamustina

Country Status (16)

Country Link
US (12) US8609707B2 (hr)
EP (3) EP3895694A1 (hr)
JP (2) JP5795600B2 (hr)
CA (1) CA2787568C (hr)
CY (2) CY1118769T1 (hr)
DK (2) DK3158991T3 (hr)
ES (2) ES2609106T5 (hr)
HR (2) HRP20161771T4 (hr)
HU (2) HUE031208T2 (hr)
LT (2) LT3158991T (hr)
PL (2) PL2528602T5 (hr)
PT (2) PT2528602T (hr)
RS (2) RS55491B2 (hr)
SI (2) SI3158991T1 (hr)
SM (1) SMT201700043B (hr)
WO (1) WO2011094565A1 (hr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2528602T5 (pl) 2010-01-28 2020-09-07 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
WO2013112762A1 (en) * 2012-01-24 2013-08-01 Innopharma, Inc. Bendamustine compositions and methods therefore
CN104203235B (zh) * 2012-02-14 2018-11-23 赛多斯有限责任公司 苯达莫司汀的制剂
PL3533447T3 (pl) * 2012-03-20 2023-07-17 Eagle Pharmaceuticals, Inc. Ciekłe kompozycje bendamustyny do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
SI2827862T1 (sl) * 2012-03-20 2024-03-29 Eagle Pharmaceuticals, Inc. Formulacije bendamustina
CA2922099C (en) 2013-08-27 2022-11-29 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
MX2016003566A (es) * 2013-09-20 2016-06-02 Santen Pharmaceutical Co Ltd Composicion que contiene polietilen glicol.
US20160235717A1 (en) * 2013-10-11 2016-08-18 Luitpold Pharmaceuticals, Inc. Bendamustine pharmaceutical compositions
EP3116481A1 (en) * 2014-03-13 2017-01-18 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
WO2016005995A2 (en) * 2014-07-10 2016-01-14 Leiutis Pharmaceuticals Pvt. Ltd. Glycol free stable liquid compositions of bendamustine
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
JP2018532806A (ja) * 2015-11-04 2018-11-08 キセラ バイオファーマシューティカルズ インコーポレイテッド デオキシコール酸およびその塩による蓄積脂肪の処置方法
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
JP7464995B2 (ja) * 2018-03-29 2024-04-10 プロジェクト ファーマシューティクス ゲーエムベーハー 液体薬学的製剤
JP2021534253A (ja) 2018-08-17 2021-12-09 ホスピーラ オーストラリア ピーティーワイ リミテッド 液体ベンダムスチン医薬組成物
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
JP2020090481A (ja) * 2018-11-27 2020-06-11 日本化薬株式会社 ベンダムスチンを含有する溶液製剤
JP7235288B2 (ja) * 2019-01-07 2023-03-08 コーアイセイ株式会社 ベンダムスチンの液体製剤
WO2020170104A1 (en) * 2019-02-18 2020-08-27 Shilpa Medicare Limited Liquid bendamustine parenteral compositions
JPWO2021161876A1 (hr) * 2020-02-10 2021-08-19
CA3235585A1 (en) 2021-10-22 2023-04-27 Andreas Schutz Liquid pharmaceutical formulation
GB202118175D0 (en) 2021-12-15 2022-01-26 Arecor Ltd Novel composition
US11707450B1 (en) 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80967C (hr)
DE159289C (hr) * 1903-10-08 1905-03-16
US4071620A (en) 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
DD152989A1 (de) 1980-09-11 1981-12-16 Klaus Kunze Anordnung zur korrektur von soll-und istwerten
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de) * 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
US5223515A (en) 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
KR100335549B1 (ko) 1993-10-27 2002-11-29 파마시아 앤드 업존 캄파니 안정화된프로스타글란딘e1
CA2181241C (en) * 1994-01-24 2000-04-25 Dadi Jamshed Dhabhar Process for solubilizing difficultly soluble pharmaceutical actives
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
JP2002511878A (ja) 1997-07-01 2002-04-16 アセロジエニクス・インコーポレイテツド 抗酸化剤による過増殖状態の治療の増強
CN1141097C (zh) * 1998-04-20 2004-03-10 卫材株式会社 含有稳定化的苯并咪唑类化合物的组合物
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6989139B2 (en) 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
CA2413328A1 (en) 2000-06-21 2001-12-27 Milind Rajopadhye Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
WO2001098294A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
EP1311292A2 (en) 2000-06-21 2003-05-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
WO2002004030A2 (en) 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
EP1553940B1 (en) * 2002-07-30 2008-02-13 Wyeth Parenteral formulations containing a rapamycin hydroxyester
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
AU2005317047A1 (en) 2004-11-05 2006-06-22 Cephalon, Inc. Cancer treatments
BRPI0516790A (pt) 2004-11-22 2008-09-30 Venus Remedies Ltd formulação de aceclofenac parenteral lìquida não aquosa , seus processos de preparação e métodos de tratamento
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
ATE509634T1 (de) 2005-04-08 2011-06-15 Amylin Pharmaceuticals Inc Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN1850048A (zh) 2006-06-09 2006-10-25 山东蓝金生物工程有限公司 一种含血管抑制剂的抗癌缓释注射剂
JPWO2008020584A1 (ja) 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
EP2073802A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
DE102007003184A1 (de) 2007-01-22 2008-07-24 Orlowski, Michael, Dr. Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en) 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched bendamustine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN102164579B (zh) * 2008-09-25 2014-10-15 赛福伦公司 苯达莫司汀的液体配制品
US8076366B2 (en) 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base
CA2753641C (en) 2009-02-25 2014-09-16 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
CN102413816A (zh) 2009-04-28 2012-04-11 赛福伦公司 苯达莫司汀的口服制剂
CN101584668A (zh) 2009-06-19 2009-11-25 江苏奥赛康药业有限公司 盐酸苯达莫司汀冻干粉针剂
WO2010148288A2 (en) 2009-06-19 2010-12-23 Lyotropic Therapeutics, Inc. Pharmaceutical formulations with low aqueous levels of free unbound drug
US20110015245A1 (en) 2009-07-20 2011-01-20 Valery Alakhov Bendamustine amphiphilic cationic compositions
US8389558B2 (en) 2009-07-20 2013-03-05 Supratek Pharma Inc. Bendamustine amphiphilic anionic compositions
US7772274B1 (en) * 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
PL2528602T5 (pl) 2010-01-28 2020-09-07 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9655898B2 (en) 2010-07-28 2017-05-23 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
EP2635558A4 (en) 2010-11-01 2014-08-06 Shilpa Medicare Ltd PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
CN104105708B (zh) 2011-12-05 2018-04-03 X博迪生物科学公司 PDGF受体β结合多肽
CN106117330B (zh) 2011-12-05 2019-12-06 伯乐实验室公司 重组脱酰胺化麦醇溶蛋白抗原
WO2013112762A1 (en) 2012-01-24 2013-08-01 Innopharma, Inc. Bendamustine compositions and methods therefore
CN104203235B (zh) 2012-02-14 2018-11-23 赛多斯有限责任公司 苯达莫司汀的制剂
SI2827862T1 (sl) 2012-03-20 2024-03-29 Eagle Pharmaceuticals, Inc. Formulacije bendamustina
PL3533447T3 (pl) 2012-03-20 2023-07-17 Eagle Pharmaceuticals, Inc. Ciekłe kompozycje bendamustyny do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
JP6331468B2 (ja) 2014-02-27 2018-05-30 住友ベークライト株式会社 金属ラミネート用フィルム、ラミネート金属板および金属容器
US11707450B1 (en) * 2022-03-03 2023-07-25 Slayback Pharma Llc Stable pharmaceutical compositions of bendamustine

Also Published As

Publication number Publication date
CY1124262T1 (el) 2022-07-22
US20240075013A1 (en) 2024-03-07
DK2528602T3 (en) 2017-01-23
EP2528602A1 (en) 2012-12-05
PL2528602T5 (pl) 2020-09-07
EP2528602A4 (en) 2014-01-22
EP3895694A1 (en) 2021-10-20
JP2013518130A (ja) 2013-05-20
CA2787568C (en) 2019-04-02
ES2609106T3 (es) 2017-04-18
EP2528602B1 (en) 2016-10-05
HRP20210915T1 (hr) 2021-10-01
SI3158991T1 (sl) 2021-10-29
SI2528602T1 (sl) 2017-03-31
RS62327B1 (sr) 2021-10-29
EP3158991A1 (en) 2017-04-26
LT3158991T (lt) 2021-07-12
HUE054836T2 (hu) 2021-10-28
US20110184036A1 (en) 2011-07-28
US9265831B2 (en) 2016-02-23
JP2016020365A (ja) 2016-02-04
CA2787568A1 (en) 2011-08-04
ES2875374T3 (es) 2021-11-10
US11103483B2 (en) 2021-08-31
WO2011094565A1 (en) 2011-08-04
US11872214B2 (en) 2024-01-16
US20160143887A1 (en) 2016-05-26
US9572796B2 (en) 2017-02-21
RS55491B2 (sr) 2020-11-30
US10010533B2 (en) 2018-07-03
PL3158991T3 (pl) 2021-09-27
EP2528602B2 (en) 2020-02-12
HUE031208T2 (hu) 2017-07-28
PL2528602T3 (pl) 2017-03-31
US20180296536A1 (en) 2018-10-18
US20140024691A1 (en) 2014-01-23
EP3158991B1 (en) 2021-03-17
DK3158991T3 (da) 2021-06-14
CY1118769T1 (el) 2017-07-12
LT2528602T (lt) 2017-02-27
US11844783B2 (en) 2023-12-19
RS55491B1 (sr) 2017-04-28
US9572797B2 (en) 2017-02-21
DK2528602T4 (da) 2020-04-27
US20180000789A1 (en) 2018-01-04
US8609707B2 (en) 2013-12-17
US20230115693A1 (en) 2023-04-13
US20230115164A1 (en) 2023-04-13
US20180296535A1 (en) 2018-10-18
US20160143888A1 (en) 2016-05-26
JP5795600B2 (ja) 2015-10-14
JP6133943B2 (ja) 2017-05-24
ES2609106T5 (es) 2020-11-10
SI2528602T2 (sl) 2020-10-30
PT3158991T (pt) 2021-06-23
US20210393594A1 (en) 2021-12-23
US20190350904A1 (en) 2019-11-21
HRP20161771T4 (hr) 2020-08-07
PT2528602T (pt) 2017-01-12
SMT201700043B (it) 2017-03-08

Similar Documents

Publication Publication Date Title
HRP20161771T1 (hr) Formulacije bendamustina
EP2814487A4 (en) BENDAMUSTIN FORMULATIONS
FI2827862T3 (fi) Bendamustiinin formulaatioita
ZA201306016B (en) Bendamustine formulations
EP2552210A4 (en) FORMULAS FROM MAZINDOL
EP2595660A4 (en) ANIONIC-CATIONIC BENDAMUSTIN CYCLOPOLYSACCHARIDE COMPOSITIONS
IL224192A (en) Compositions of Vitamin 14 – Epi Analogs d
AP2013006687A0 (en) Formulations
GB201110193D0 (en) Formulations
GB201013513D0 (en) Formulations
ZA201300196B (en) Formulations
GB201018649D0 (en) Formulations
GB201018648D0 (en) Formulations
GB201018647D0 (en) Formulations
GB201018645D0 (en) Formulations
GB201012589D0 (en) Formulations
GB201010494D0 (en) Formulations
GB201008470D0 (en) Formulations
GB201008358D0 (en) Formulations
GB201007959D0 (en) Formulations
GB201007702D0 (en) Formulations